performed a trial that compared RT (65Gy) alone versus RT plus chemotherapy. All patients underwent serial bronchoscopic biopsies and were found to have local control rates at one year of only 15% with RT alone and 17% with combined modality therapy. 9 It appears that local control is generally unsatisfactory following RT or RT plus chemotherapy. This should come as no surprise as studies performed over 30 years ago suggested that larger epithelial tumors required doses much greater than 60Gy to achieve local control. 14 In the classic article regarding RT dose-response, Fletcher and Shukovsky wrote that it would require 80-90Gy, conventionally fractionated, to locally control 56% of adenocarcinomas of the breast >5cm in diameter. 14 There is no reason to believe NSCLCs would respond differently, as they are often at least this large and most commonly adenocarcinomas in the US. One major shift in treatment strategy was the irradiation of radiographically apparent gross disease without prophylactic or elective nodal irradiation (ENI). ENI is the purposeful irradiation of radiographically uninvolved lymph nodes that may contain cancer cells. ENI was originally employed because imaging was so poor prior to computed tomography, when plain radiographs were used to define tumor volumes for RT planning.
There were several reasons for the shift in philosophy away from ENI.
The dose of radiation commonly employed (60Gy/30 fractions) was not enough to sterilize bulky epithelial tumors. 14 It was believed that simply increasing the dose delivered to the large volumes of the chest included when prophylactically treating lymph nodes was likely to result in unacceptable toxicity. 19 Additionally, irradiating clinically uninvolved nodal areas prophylactically did not appear rational when the gross tumor was infrequently controlled. 9 The vast majority of dose-escalation trials do not include ENI to minimize the volume of normal tissues irradiated and decrease the risk of toxicity. arm achieved a better five-year local control rate than those in the ENI arm (51 versus 36%; p=0.03). 34 The radiation pneumonitis rate in patients with IFI was lower than in those with ENI (17 versus 29%, p=0.04). Similar trends appeared in radiation esophagitis, myelosuppression, and radiation pericarditis rates between the two arms, although these differences were not significant. 
Future Directions and Conclusions
Future improvements in imaging and RT-delivery systems will lead to better outcomes for patients with unresectable NSCLC. These will include greater precision in defining tumor, adenopathy, and normal surrounding tissues spatially. In particular, thymidine positron-emission tomography scanning may better differentiate between nodes involved with tumor and inflammation and help guide more precise RT. Molecular analysis of tumors will allow physicians to choose more effective chemo-and biological therapies to combine with radiation. Newer delivery systems will allow the administration of a greater RT dose to the tumor and less to the surrounding normal structures. Technologies that are likely to be helpful in accomplishing these goals include the ever improving RT planning computers, intensity-modulated RT, image-guided RT, stereotactic body RT, and charged heavy-particle (hadron) RT. n
